These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28991707)

  • 1. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
    Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
    J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
    Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
    J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
    Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
    AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
    Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
    Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
    Jain RS; Khan I; Kandelwal K; Desai T
    Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma.
    Sun C; Han J; Lin Y; Qi X; Li C; Liu J; Qiu F
    Front Immunol; 2022; 13():986473. PubMed ID: 36059526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.
    Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P
    J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology.
    Saridas F; Mesut G; Ceylan CY; Ozpar R; Ozsen M; Koc ER; Tolunay S; Hakyemez B; Turan OF
    Mult Scler Relat Disord; 2024 May; 85():105537. PubMed ID: 38460252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
    Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
    Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.
    Kobayashi M; Shimizu Y; Shibata N; Uchiyama S
    J Neurol; 2014 Oct; 261(10):1902-10. PubMed ID: 25034274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
    Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
    Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumefactive demyelinating lesions: A comprehensive review.
    Algahtani H; Shirah B; Alassiri A
    Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
    Jeong IH; Kim SH; Hyun JW; Joung A; Cho HJ; Kim HJ
    J Neurol Sci; 2015 Nov; 358(1-2):118-24. PubMed ID: 26333950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuro-oncology dilemma: Tumour or tumefactive demyelinating lesion.
    Abdoli M; Freedman MS
    Mult Scler Relat Disord; 2015 Nov; 4(6):555-66. PubMed ID: 26590662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
    Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
    Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
    Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
    Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features-A case series.
    Boyle T; Fernando SL; Drummond J; Fontes A; Parratt J
    Front Neurol; 2023; 14():1092373. PubMed ID: 36816572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
    Sánchez P; Meca-Lallana V; Vivancos J
    Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopsy-Supported Tumefactive Demyelination of the Central Nervous System in Children.
    Hanumanthe SB; Francisco C; Hart J; Graves J; Waubant E
    J Child Neurol; 2016 Dec; 31(14):1528-1533. PubMed ID: 27572815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
    Di Gregorio M; Torri Clerici VLA; Fenu G; Gaetani L; Gallo A; Cavalla P; Ragonese P; Annovazzi P; Gajofatto A; Prosperini L; Landi D; Nicoletti CG; Di Carmine C; Totaro R; Nociti V; De Fino C; Ferraro D; Tomassini V; Tortorella C; Righini I; Amato MP; Manni A; Paolicelli D; Iaffaldano P; Lanzillo R; Moccia M; Buttari F; Fantozzi R; Cerqua R; Zagaglia S; Farina D; De Luca G; Buscarinu MC; Pinardi F; Cocco E; Gasperini C; Solaro CM; Di Filippo M
    Eur J Neurol; 2021 Apr; 28(4):1299-1307. PubMed ID: 33305459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.